“First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma”, jkcvhl, vol. 12, no. 2, pp. 27–36, Apr. 2025, doi: 10.15586/jkcvhl.v12i2.387.